honestly, revenues are due to go up at least 150% when reported tomorrow, after being up 115% in the last quarter and 75% in the quarter before -- so the already amazing growth is accelerating
does anyone know of another biotech that has done so well
this Fact Sheet makes it crystal clear that Elite has what FDA wants
google this string, put a DOT and an htm at the end, and hopefully it comes up -- fda.gov/NewsEvents/Newsroom/FactSheets/ucm484714
reaction varies. if it is something new for hep-C or liver cancer or breast cancer, then the stock can really move because those diseases are in vogue currently, just like every new AIDS drug used to be
ELTP actually should have moved with successful completion of the abuse resistant studies. the fact that it didn't indicates it is off the radar. which is why neither filing did not have much affect. but there should be some action upon acceptance, and then some real fireworks come approval
"BETHESDA, Md., April 15, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of the first $15 million funding by a single institutional investor of the registered direct placement of up to $32 million which was announced by the Company last week. These first 2.27 million shares of common stock were sold for $6.60 per share.
"With the recent positive developments in our European programs, substantial additional DCVax-L production capacity will be needed," commented Linda F. Powers, NW Bio CEO. "Today's funding will enable us to move forward on the development of this capacity for an increasing number of patients, including early access patients outside of our clinical trials involving some initial early revenues."
casediagnostics • Aug 21, 2014 4:49 PM
Who is the best Partner Candidate?
A buyout at only $10/per share would be valuing Elite at 500,000,000 X 10 = $ 5 Billion.
Elite's ART could be worth far more than that, since its plug-in-and-play capacity allows it to be mated with a variety of other medications.
Looking to maximize ART value, therefore, Elite should be looking for a partner who has the highest number of potential ART-relevant mate candidates.
casediagnostics • Aug 21, 2014 9:33 PM
I am not suggesting that $10 is a probable figure.
And I rounded the share count down to 500 million.
That said, to the right company, Elite's ART might be worth $10 / share or higher.
i've gpt my money on ELTP
Epic began when they got special funding from New Jersey under the "Economic Development Act" to buy an annex that Sandoz was getting ready to shutter during the recession in 2008. it helped the community keep something like 40 jobs -- they now employ about 200. Epic took over the facility, and Sandoz became their biggest customer as Epic produced the same compounds for Sandoz cheaper than Sandoz because, of course, Epic didn't have the same pricey overhead
btw -- "year established" is more likely 1986 if reference is to the building, but could be 1886 if referring to Sandoz -- and, Epic is(!) the largest contract manufacturer in this country for Sandoz
FDA reviewed everything that had been done and only required a mini phase III for efficacy which, ironically, indicates FDA was concerned ELI-200's abuse resistance might be so robust that it would not even provide pain relief
the successful phase III has answered the last of FDA's questions, and we know that because Hakim had been checking and re-checking with them leading up to filing, so approval is on its way
hmm-mm, one has been marketed for almost five years and has not made much of a ripple, another was unloaded by Johnson & Johnson even after they had been trying to market it, the third one has already been paying penalties for improper marketing/violating the label which has cost them a CEO as lawsuits continue, and all were approved for limited use
nice steal from motley fool, billieboy fool, but oxy remains the go to drug for breakthrough pain and Hakim is about to bring the best and safest to market soon
you can hear the Elite dragster coming to the line now -- pa, pam, pam, pa, pa, pam...
you asked this same question of the board last month, and you have also asked the board to explain the difference between ELI-200, ELI-201, and ELI-202
think it's time you did a little dd for yourself
quickly you will discover that the competition right now is NON-abuse resistant painkillers, and Elite has a distinct and obvious advantage over them all
next you will find descriptions of approaches to abuse resistance that have been or are being tried by potential future competitors, and you will learn of their shortcomings. as an example, egalet's drug is not snort proof (it's just harder to crush) and collegium's extampza has binders that may affect absorption rates and are toxic to some people
in the end you will conclude that Elite has the best approach by far and, hopefully, you will have learned to do at least a modicum of dd before bothering the board
by base.jumper55 • Nov 10, 2015 8:03 PM
I'm so impressed by all the things this company has accomplished in the past 2 years. This company has truly overcome so many obstacles and shortfalls, it's amazing how far they have come. A little over two years ago they had defaulted bonds, no money, minimal generic profile, minimal staff and laughable revenues ($600,000 per quarter I believe). They had to borrow money from the CEO even! They were drowning. No NDA in sight!
Here we are today reporting $2.7 mil revenues TTM (almost 10 mil for the last 6 months), 3 new generics coming online in the next 6 months, submitting their first ever NDA to the FDA in the next two months, increasing personnel, increased facility size by double, and $10+ mil in the bank. You can't do much better than that.
If you have any doubt about this company, just look at where they were 2 years ago and rest assured your money is in a sound company with competent leadership. Only downside is it lives in the penny stock world with constant price fluctuations due to god knows what. My2cents. Happy investing
well, eglt is way ahead of Elite so you absolutely should switch horses ASAP
and don't worry if you hear that arymo isn't really snort proof, just a little harder to crush, and that FDA did not review their abuse resistant studies and work with them like they did with Hakim before they filed
same thing if someone says egalet used potentially harmful inactive ingredients in their 'guardian technology' manufacturing process for this hard as a bullet pill -- just ignore
and don't concern yourself that their oxyado isn't selling worth a darn, or that insiders are selling a lot more than a darn, or that the stock barely burped on this news even though it is down substantially for the year, or that short interest is at 30%, or that their message board is stone cold silent
let me repeat that last one -- their message board is stone cold silent, you would have no chat room to unload all your angst
all in all, you really, really need to switch, absolutely, asap
keep in mind, the protocols for the phase III that Elite has successfully completed were basically given to Elite by the FDA specifically for ELI-200
the FDA also asked Elite to do a labeling study concurrent with the phase III mini-trial and in advance of submitting ELI-200 for approval
sure sounds like the FDA is in Elite's camp and is prepared to expedite ELI-200 approval
whole process is described at this site...
Elite is not going to be showing much mercy in the new year
FDA acceptance is going to feel like a cruise missile
and then the real bunker buster slams home when ELI-200 is approved
word has it that CVS is already running low on lube
he was given rights to almost 145 million shares for coming on as CEO and bringing a baker's dozen of generic drugs with him. if he did not choose to exercise the rights then Elite would have had to pay him $10 million (145 million times .07 per share which was the stock price when the agreement was reached) but he chose to exercise well before he had to
he already had 11 million shares -- some say he bought them on the open market, others say it was payment under a previous three drug agreement between Elite and Mikah (his private company) -- and he has since bought almost 2 million shares on the open market for a trust fund. that is probably the 13 million number that yahoo is reporting
and his salary is paid in shares which adds a few million a year
all told, he should have about 165-170 million shares
and Hakim has been able to accomplish all these improvements to the balance sheet while adding major staff and upgrading equipment
the relevance of this is that it means Hakim is no longer hat in hand, and does not NEED a partner. though, as he has said, give him $100 million and he could really speed up the abuse resistant pipeline
Jerry first said that, well before Hakim showed up, and it is simply an admission that Elite won't be getting any lucrative exclusivity (180-day monopoly) for having a first to market and doesn't have any one generic that will cause waves but, collectively, they still represent a substantial cash flow opportunity, especially for a company the size of Elite
Hakim said in his first or second cc (believe it was when he announced Doug Plassche was coming aboard) that, long term, Elite would be a player in the generic market but the immediate focus would be on getting the first abuse resistant drug through the FDA . that is why he sent those generics over to Epic that he had brought with him from Micah -- he did not want himself or his staff to be distracted
you know, you quibble and question sometimes in a way that makes me wonder if maybe you need to do something other than live on this board day in and day out because it does not seem to make you happy